OKYO Pharma Announces Purchase of Shares by Chief Medical Officer

Summary by AI BETAClose X

OKYO Pharma announced that its Chief Medical Officer purchased 20,000 ordinary shares on NASDAQ at $1.40 per share, representing a total investment of $28,000. This share purchase by a key executive may signal confidence in the company's future prospects as it prepares to initiate a global Phase 3 pivotal clinical trial for urcosimod in the second half of the year, which will enroll approximately 111 patients to evaluate its efficacy in treating neuropathic corneal pain.

Disclaimer*

UK 100

Latest directors dealings